OpenLB
Open Library of Bioscience
Advanced Search
The Cochrane database of systematic reviews
03 16, 2020;3 CD011154.

Topical benzoyl peroxide for acne.

Zhirong Yang, Yuan Zhang, Elvira Lazic Mosler, Jing Hu, Hang Li, Yanchang Zhang, Jia Liu, Qian Zhang
Author Information
  1. Zhirong Yang: School of Clinical Medicine, University of Cambridge, Primary Care Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, 2 Worts' Causeway, Cambridge, UK, CB1 8RN.
  2. Yuan Zhang: McMaster University, Department of Health Research Methods, Evidence, and Impact, 1280 Main Street West, Hamilton, ON, Canada, L8S 4K1.
  3. Elvira Lazic Mosler: Catholic University of Croatia, Department of Nursing, Ilica 242, Zagreb, Croatia, 10000.
  4. Jing Hu: School of Public Health, Peking University, Centre for Evidence Based Medicine and Clinical Research, Department of Epidemiology and Biostatistics, Beijing, China, 100191.
  5. Hang Li: Peking University First Hospital, Department of Dermatology and Venereology, 8 Xishiku Main Street, Beijing, Xicheng District, China, 100034.
  6. Yanchang Zhang: Yale School of Public Health, Department of Chronic Disease Epidemiology, 367 Cedar ST RM 704, New Haven, Connecticut, USA, 06510.
  7. Jia Liu: Xuanwu Hospital, Capital Medical University, Department of Neurology, Changchun Street 45, Beijing, China, 100053.
  8. Qian Zhang: The University of Nottingham, c/o Cochrane Skin Group, A103, King's Meadow Campus, Lenton Lane, Nottingham, UK, NG7 2NR.
PMID: 32175593 DOI: 10.1002/14651858.CD011154.pub2

Abstract

BACKGROUND: Acne is a common, economically burdensome condition that can cause psychological harm and, potentially, scarring. Topical benzoyl peroxide (BPO) is a widely used acne treatment; however, its efficacy and safety have not been clearly evaluated.
OBJECTIVES: To assess the effects of BPO for acne.
SEARCH METHODS: We searched the following databases up to February 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of relevant randomised controlled trials (RCTs) and systematic reviews.
SELECTION CRITERIA: We included RCTs that compared topical BPO used alone (including different formulations and concentrations of BPO) or as part of combination treatment against placebo, no treatment, or other active topical medications for clinically diagnosed acne (used alone or in combination with other topical drugs not containing BPO) on the face or trunk.
DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as expected by Cochrane. Primary outcome measures were 'participant global self-assessment of acne improvement' and 'withdrawal due to adverse events in the whole course of a trial'. 'Percentage of participants experiencing any adverse event in the whole course of a trial' was a key secondary outcome.
MAIN RESULTS: We included 120 trials (29,592 participants randomised in 116 trials; in four trials the number of randomised participants was unclear). Ninety-one studies included males and females. When reported, 72 trials included participants with mild to moderate acne, 26 included participants with severe acne, and the mean age of participants ranged from 18 to 30 years. Our included trials assessed BPO as monotherapy, as add-on treatment, or combined with other active treatments, as well as BPO of different concentrations and BPO delivered through different vehicles. Comparators included different concentrations or formulations of BPO, placebo, no treatment, or other active treatments given alone or combined. Treatment duration in 80 trials was longer than eight weeks and was only up to 12 weeks in 108 trials. Industry funded 50 trials; 63 trials did not report funding. We commonly found high or unclear risk of performance, detection, or attrition bias. Trial setting was under-reported but included hospitals, medical centres/departments, clinics, general practices, and student health centres. We reported on outcomes assessed at the end of treatment, and we classified treatment periods as short-term (two to four weeks), medium-term (five to eight weeks), or long-term (longer than eight weeks). For 'participant-reported acne improvement', BPO may be more effective than placebo or no treatment (risk ratio (RR) 1.27, 95% confidence interval (CI) 1.12 to 1.45; 3 RCTs; 2234 participants; treatment for 10 to 12 weeks; low-certainty evidence). Based on low-certainty evidence, there may be little to no difference between BPO and adapalene (RR 0.99, 95% CI 0.90 to 1.10; 5 RCTs; 1472 participants; treatment for 11 to 12 weeks) or between BPO and clindamycin (RR 0.95, 95% CI 0.68 to 1.34; 1 RCT; 240 participants; treatment for 10 weeks) (outcome not reported for BPO versus erythromycin or salicylic acid). For 'withdrawal due to adverse effects', risk of treatment discontinuation may be higher with BPO compared with placebo or no treatment (RR 2.13, 95% CI 1.55 to 2.93; 24 RCTs; 13,744 participants; treatment for 10 to 12 weeks; low-certainty evidence); the most common causes of withdrawal were erythema, pruritus, and skin burning. Only very low-certainty evidence was available for the following comparisons: BPO versus adapalene (RR 1.85, 95% CI 0.94 to 3.64; 11 RCTs; 3295 participants; treatment for 11 to 24 weeks; causes of withdrawal not clear), BPO versus clindamycin (RR 1.93, 95% CI 0.90 to 4.11; 8 RCTs; 3330 participants; treatment for 10 to 12 weeks; causes of withdrawal included local hypersensitivity, pruritus, erythema, face oedema, rash, and skin burning), erythromycin (RR 1.00, 95% CI 0.07 to 15.26; 1 RCT; 60 participants; treatment for 8 weeks; withdrawal due to dermatitis), and salicylic acid (no participants had adverse event-related withdrawal; 1 RCT; 59 participants; treatment for 12 weeks). There may be little to no difference between these groups in terms of withdrawal; however, we are unsure of the results because the evidence is of very low certainty. For 'proportion of participants experiencing any adverse event', very low-certainty evidence leaves us uncertain about whether BPO increased adverse events when compared with placebo or no treatment (RR 1.40, 95% CI 1.15 to 1.70; 21 RCTs; 11,028 participants; treatment for 10 to 12 weeks), with adapalene (RR 0.71, 95% CI 0.50 to 1.00; 7 RCTs; 2120 participants; treatment for 11 to 24 weeks), with erythromycin (no participants reported any adverse events; 1 RCT; 89 participants; treatment for 10 weeks), or with salicylic acid (RR 4.77, 95% CI 0.24 to 93.67; 1 RCT; 41 participants; treatment for 6 weeks). Moderate-certainty evidence shows that the risk of adverse events may be increased for BPO versus clindamycin (RR 1.24, 95% CI 0.97 to 1.58; 6 RCTs; 3018 participants; treatment for 10 to 12 weeks); however, the 95% CI indicates that BPO might make little to no difference. Most reported adverse events were mild to moderate, and local dryness, irritation, dermatitis, erythema, application site pain, and pruritus were the most common.
AUTHORS' CONCLUSIONS: Current evidence suggests that BPO as monotherapy or add-on treatment may be more effective than placebo or no treatment for improving acne, and there may be little to no difference between BPO and either adapalene or clindamycin. Our key efficacy evidence is based on participant self-assessment; trials of BPO versus erythromycin or salicylic acid did not report this outcome. For adverse effects, the evidence is very uncertain regarding BPO compared with adapalene, erythromycin, or salicylic acid. However, risk of treatment discontinuation may be higher with BPO compared with placebo or no treatment. Withdrawal may be linked to tolerability rather than to safety. Risk of mild to moderate adverse events may be higher with BPO compared with clindamycin. Further trials should assess the comparative effects of different preparations or concentrations of BPO and combination BPO versus monotherapy. These trials should fully assess and report adverse effects and patient-reported outcomes measured on a standardised scale.

References

Psychother Psychosom. 1993;60(3-4):207-10 [PMID: 8272479]
Br J Dermatol. 2000 Jun;142(6):1084-91 [PMID: 10848729]
J Drugs Dermatol. 2009 Sep;8(9):812-8 [PMID: 19746673]
Br J Dermatol. 2008 Jan;158(1):122-9 [PMID: 18047518]
Br J Dermatol. 1994 Mar;130(3):329-36 [PMID: 8148274]
J Drugs Dermatol. 2017 Jun 1;16(6):582-589 [PMID: 28686776]
J Dermatol. 2018 Aug;45(8):951-962 [PMID: 29905384]
Br J Dermatol. 2009 Jan;160(1):132-6 [PMID: 19067711]
Health Technol Assess. 2005 Jan;9(1):iii-212 [PMID: 15588555]
Cutis. 1982 Jun;29(6):638-40, 644-5 [PMID: 6213380]
J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1176-82 [PMID: 27075705]
J Eur Acad Dermatol Venereol. 2007 Mar;21(3):311-9 [PMID: 17309451]
Cochrane Database Syst Rev. 2020 Mar 16;3:CD011154 [PMID: 32175593]
Curr Med Res Opin. 1977;5(3):266-8 [PMID: 162728]
J Am Acad Dermatol. 2002 Aug;47(2):231-40 [PMID: 12140469]
J Dermatolog Treat. 2009;20(5):289-92 [PMID: 19459079]
J Am Acad Dermatol. 2007 Apr;56(4):651-63 [PMID: 17276540]
Clin Exp Dermatol. 2000 Jan;25(1):16-20 [PMID: 10671963]
Br J Dermatol. 2004 Aug;151(2):481-4 [PMID: 15327558]
Cutis. 2003 Aug;72(2):167-72 [PMID: 12953944]
J Drugs Dermatol. 2014 Feb;13(2):170-4 [PMID: 24509968]
Br J Dermatol. 2016 Feb;174(2):287-95 [PMID: 26779929]
J Am Acad Dermatol. 1998 Aug;39(2 Pt 3):S34-7 [PMID: 9703121]
Br J Dermatol. 1988 Nov;119(5):615-22 [PMID: 2974719]
J Am Acad Dermatol. 1983 Dec;9(6):933-6 [PMID: 6227643]
Clin Exp Dermatol. 2012 Mar;37(2):112-7 [PMID: 22103435]
Dermatology. 2016;232(3):371-80 [PMID: 27220773]
PLoS Med. 2009 Jul 21;6(7):e1000097 [PMID: 19621072]
PLoS Med. 2009 Jul 21;6(7):e1000100 [PMID: 19621070]
Trials. 2010 Jul 12;11:77 [PMID: 20624287]
Nihon Yakurigaku Zasshi. 2015 Oct;146(4):225-32 [PMID: 26656967]
BMJ. 2010 Mar 23;340:c332 [PMID: 20332509]
J Drugs Dermatol. 2015 Apr;14(4):381-4 [PMID: 25844612]
Cutis. 2009 Oct;84(4):223-9 [PMID: 19911678]
J Drugs Dermatol. 2006 Mar;5(3):256-61 [PMID: 16573259]
J Dermatolog Treat. 2012 Feb;23(1):26-34 [PMID: 22103674]
Br J Dermatol. 1995 Feb;132(2):204-8 [PMID: 7888356]
Cutis. 2003 Jul;72(1 Suppl):16-9 [PMID: 12887173]
Clin Ther. 2002 May;24(5):773-85 [PMID: 12075945]
Int J Dermatol. 1996 Mar;35(3):209-11 [PMID: 8655242]
J Clin Aesthet Dermatol. 2017 Jun;10(6):36-43 [PMID: 28979655]
J Clin Aesthet Dermatol. 2009 Nov;2(11):21-6 [PMID: 20725576]
Clin Ther. 2002 Jul;24(7):1117-33 [PMID: 12182256]
J Clin Aesthet Dermatol. 2016 Jul;9(7):23-29 [PMID: 28331557]
J Am Acad Dermatol. 2010 Jul;63(1):52-62 [PMID: 20488582]
Clin Dermatol. 2004 Sep-Oct;22(5):439-44 [PMID: 15556732]
Arch Dermatol. 1983 Jun;119(6):480-1 [PMID: 6222700]
Skin Therapy Lett. 2009 Jul-Aug;14(6):4-5 [PMID: 19609474]
J Drugs Dermatol. 2011 Dec;10(12):1382-96 [PMID: 22134562]
J Clin Aesthet Dermatol. 2016 Oct;9(10):50-54 [PMID: 27847549]
BMJ. 2002 Aug 31;325(7362):475-9 [PMID: 12202330]
J Dermatol. 2014 Sep;41(9):795-801 [PMID: 25132461]
J Drugs Dermatol. 2012 May;11(5):643-8 [PMID: 22527435]
Am J Clin Dermatol. 2019 Jun;20(3):345-365 [PMID: 30674002]
J Drugs Dermatol. 2010 Jul;9(7):805-13 [PMID: 20677537]
AAPS PharmSciTech. 2001 Jul 17;2(3):E-TN4 [PMID: 14727868]
Indian J Dermatol Venereol Leprol. 2013 May-Jun;79(3):300-9 [PMID: 23619435]
Cutis. 2010 Feb;85(2):94-104 [PMID: 20349684]
J Invest Dermatol. 2003 Jul;121(1):20-7 [PMID: 12839559]
J Eur Acad Dermatol Venereol. 2008 May;22(5):629-31 [PMID: 18410627]
Curr Med Res Opin. 1981;7(6):370-3 [PMID: 6453695]
Arch Dermatol Res. 2015 Nov;307(9):757-66 [PMID: 26048131]
J Clin Aesthet Dermatol. 2019 Jul;12(7):34-50 [PMID: 31531161]
Acta Derm Venereol. 1981;61(3):267-9 [PMID: 6167116]
Cutis. 2012 Jun;89(6):287-93 [PMID: 22838094]
G Ital Dermatol Venereol. 2016 Jun;151(3):230-8 [PMID: 25236322]
Drugs Exp Clin Res. 2003;29(3):101-5 [PMID: 14708455]
Practitioner. 1980 Sep;224(1347):952-4 [PMID: 6449698]
Clin Exp Dermatol. 2012 May;37 Suppl 1:1-6 [PMID: 22486762]
J Eur Acad Dermatol Venereol. 2009 Mar;23(3):245-50 [PMID: 19438817]
J Cosmet Dermatol. 2009 Mar;8(1):19-23 [PMID: 19250161]
J Drugs Dermatol. 2015 Dec;14(12):1418-21 [PMID: 26659934]
Cutis. 1980 Jan;25(1):90-2 [PMID: 6444379]
J Cutan Med Surg. 2003 Jan-Feb;7(1):31-7 [PMID: 12362264]
J Drugs Dermatol. 2010 Jun;9(6):655-64 [PMID: 20645527]
Skin Therapy Lett. 2010 Nov-Dec;15(10):5-7 [PMID: 21076800]
N Engl J Med. 2005 Apr 7;352(14):1463-72 [PMID: 15814882]
Br J Dermatol. 1996 Jan;134(1):107-13 [PMID: 8745894]
Am J Clin Dermatol. 2018 Apr;19(2):275-286 [PMID: 29549588]
CMAJ. 2011 Apr 19;183(7):E430-5 [PMID: 21398228]
Br J Dermatol. 1983 Feb;108(2):199-204 [PMID: 6218815]
Clin Exp Dermatol. 1992 May;17(3):165-8 [PMID: 1451291]
Appl Ther. 1966 Jul;8(7):624-5 [PMID: 4223595]
J Drugs Dermatol. 2008 Jun;7(6):534-8 [PMID: 18561583]
Clin Exp Dermatol. 2010 Jan;35(1):16-21 [PMID: 19486044]
Br J Dermatol. 2015 Feb;172(2):494-503 [PMID: 25040180]
Z Hautkr. 1984 Jul 1;59(13):873-81 [PMID: 6235682]
Am J Clin Dermatol. 2008;9(5):313-7 [PMID: 18717606]
J Drugs Dermatol. 2012 Apr;11(4):455-9 [PMID: 22453581]
G Ital Dermatol Venereol. 1989 Oct;124(10):465-70 [PMID: 2534551]
Indian J Pharmacol. 2011 Nov;43(6):628-31 [PMID: 22144763]
Br J Dermatol. 2013 Mar;168(3):474-85 [PMID: 23210645]
J Eur Acad Dermatol Venereol. 2017 Apr;31(4):737-742 [PMID: 27790756]
Cutis. 2003 Feb;71(2 Suppl):10-7 [PMID: 12630670]
CMAJ. 2016 Feb 2;188(2):118-126 [PMID: 26573753]
Cutis. 2003 Feb;71(2 Suppl):3-4 [PMID: 12630668]
Pediatr Dermatol. 2017 Nov;34(6):661-664 [PMID: 29024079]
Expert Opin Pharmacother. 2009 Oct;10(15):2555-62 [PMID: 19761357]
Lancet. 2012 Dec 15;380(9859):2197-223 [PMID: 23245608]
Curr Ther Res Clin Exp. 1973 Sep;15(9):624-9 [PMID: 4270828]
Ann Dermatol. 2014 Feb;26(1):43-52 [PMID: 24648685]
J Drugs Dermatol. 2013 Mar;12(3):277-82 [PMID: 23545909]
Med J Aust. 1990 Oct 15;153(8):455-8 [PMID: 2145499]
J Clin Aesthet Dermatol. 2015 Sep;8(9):25-32 [PMID: 26430488]
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1727-1731 [PMID: 28573779]
Int J Dermatol. 2007 Jan;46(1):89-93 [PMID: 17214729]
Int J Dermatol. 1979 Jul-Aug;18(6):485-8 [PMID: 158569]
Practitioner. 1978 Mar;220(1317):479-82 [PMID: 148043]
Cutis. 2016 Jul;98(1):21-5 [PMID: 27529706]
J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37 [PMID: 12833004]
J Clin Aesthet Dermatol. 2012 May;5(5):16-24 [PMID: 22808305]
Cutis. 2010 Aug;86(2):94-9 [PMID: 20919604]
Int J Appl Basic Med Res. 2015 May-Aug;5(2):106-10 [PMID: 26097817]
BMJ. 1997 Sep 13;315(7109):629-34 [PMID: 9310563]
J Eur Acad Dermatol Venereol. 2016 Jun;30(6):966-73 [PMID: 26915831]
J Eur Acad Dermatol Venereol. 2010 Aug;24(8):953-7 [PMID: 20337811]
J Eur Acad Dermatol Venereol. 2012 Feb;26 Suppl 1:1-29 [PMID: 22356611]
J Drugs Dermatol. 2013 Jun 1;12(6):611-8 [PMID: 23839175]
Pediatrics. 2006 Sep;118(3):1188-99 [PMID: 16951015]
Clin Exp Dermatol. 2011 Mar;36(2):119-22; quiz 123 [PMID: 20738323]
J Dermatolog Treat. 2003 Sep;14(3):166-71 [PMID: 14522627]
J Drugs Dermatol. 2005 Sep-Oct;4(5):611-8 [PMID: 16167420]
Cutis. 2010 Dec;86(6):310-8 [PMID: 21284283]
J Dermatol. 2017 Jun;44(6):635-643 [PMID: 28150367]
J Am Acad Dermatol. 2008 Nov;59(5):792-800 [PMID: 18805603]
Skin Res Technol. 2012 Feb;18(1):1-14 [PMID: 21605170]
Cutis. 2003 Feb;71(2 Suppl):27-34 [PMID: 12630672]
J Drugs Dermatol. 2012 Dec;11(12):1422-6 [PMID: 23377511]
J Drugs Dermatol. 2015 Dec;14(12):1427-35 [PMID: 26659936]
Am J Clin Dermatol. 2005;6(1):13-9 [PMID: 15675886]
Semin Cutan Med Surg. 2008 Sep;27(3):212-20 [PMID: 18786500]
J Drugs Dermatol. 2013 Feb;12(2):180-5 [PMID: 23377391]
J Drugs Dermatol. 2010 Nov;9(11):1395-401 [PMID: 21061762]
Z Hautkr. 1988 May 15;63(5):374-6 [PMID: 2970159]
Indian J Dermatol Venereol Leprol. 1998 Mar-Apr;64(2):71-4 [PMID: 20921719]
Cutis. 2001 Feb;67(2 Suppl):13-20 [PMID: 11236210]
Am J Clin Dermatol. 2012 Jun 1;13(3):141-52 [PMID: 22268388]
J Drugs Dermatol. 2010 Jan;9(1):33-40 [PMID: 20120423]
Cutis. 2007 Jul;80(1 Suppl):10-4 [PMID: 17824581]
Acta Derm Venereol. 2001 Jan-Feb;81(1):14-7 [PMID: 11411906]
J Clin Aesthet Dermatol. 2010 Jul;3(7):32-43 [PMID: 20725555]
Cutis. 2001 Feb;67(2 Suppl):21-4 [PMID: 11236211]
Cutis. 2009 May;83(5):265-72 [PMID: 19537284]
J Drugs Dermatol. 2015 Sep;14(9):969-74 [PMID: 26355615]
Clin Exp Dermatol. 1989 Sep;14(5):357-60 [PMID: 2532986]
J Clin Aesthet Dermatol. 2015 May;8(5):28-32 [PMID: 26029332]
J Am Acad Dermatol. 1997 Jun;36(6 Pt 2):S113-5 [PMID: 9204088]
Br J Dermatol. 2017 Oct;177(4):908-913 [PMID: 29052890]
Br J Dermatol. 2001 Jul;145(1):100-4 [PMID: 11453915]
An Bras Dermatol. 2015 Dec;90(6 Suppl 1):1-16 [PMID: 27168522]
J Clin Aesthet Dermatol. 2013 Sep;6(9):27-35 [PMID: 24062871]
J Eur Acad Dermatol Venereol. 2007 Mar;21(3):320-5 [PMID: 17309452]
J Drugs Dermatol. 2009 Aug;8(8):736-43 [PMID: 19663111]
Br J Dermatol. 2009 Nov;161(5):1180-9 [PMID: 19466959]
J Clin Aesthet Dermatol. 2015 Dec;8(12):22-6 [PMID: 26705445]
J Invest Dermatol. 2011 Feb;131(2):363-70 [PMID: 20844551]
Pediatr Dermatol. 2008 Jun;25 Suppl 1:1-14 [PMID: 18494684]
Br J Dermatol. 2011 Jun;164(6):1376-82 [PMID: 21457209]
Br J Dermatol. 2009 Nov;161(5):971-6 [PMID: 19857206]
Int J Dermatol. 1986 Dec;25(10):664-7 [PMID: 2948929]
Am J Clin Dermatol. 2004;5(4):261-5 [PMID: 15301572]
Cutis. 2003 Feb;71(2 Suppl):18-26 [PMID: 12630671]
Ann Dermatol Venereol. 2010 Nov;137 Suppl 2:S49-51 [PMID: 21095494]
Dermatologica. 1986;172(5):263-7 [PMID: 2943613]
Cutan Ocul Toxicol. 2019 Mar;38(1):48-54 [PMID: 30173582]
J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50 [PMID: 19376456]
Am J Clin Dermatol. 2001;2(1):33-9 [PMID: 11702619]
Cochrane Database Syst Rev. 2016 Sep 27;9:CD007917 [PMID: 27670126]
Postgrad Med J. 1999 Jun;75(884):328-31 [PMID: 10435165]
Clin Ther. 1989 Mar-Apr;11(2):264-7 [PMID: 2525420]
J Dermatol. 2017 Jul;44(7):774-782 [PMID: 28295516]
Curr Med Res Opin. 2003;19(2):135-8 [PMID: 12740158]
Cutis. 2010 Nov;86(5):263-7 [PMID: 21214129]
Br J Dermatol. 1997 Feb;136(2):235-8 [PMID: 9068739]
J Clin Aesthet Dermatol. 2008 Sep;1(3):16-20 [PMID: 21203357]
J Drugs Dermatol. 2017 Jun 1;16(6):574-581 [PMID: 28686775]
Br J Dermatol. 2006 Mar;154(3):524-32 [PMID: 16445786]
Skin Pharmacol Physiol. 2016;29(1):1-8 [PMID: 26458265]
J Drugs Dermatol. 2010 Feb;9(2):131-6 [PMID: 20214175]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2012 May;32(5):624-7 [PMID: 22679722]
Cutis. 2002 Feb;69(2 Suppl):20-9 [PMID: 12095065]
Br J Dermatol. 1984 Apr;110(4):487-92 [PMID: 6231942]
Z Hautkr. 1989 Feb 15;64(2):140-4 [PMID: 2524133]
Cutis. 2001 Feb;67(2):165-9 [PMID: 11236229]
Lancet. 1998 Jun 20;351(9119):1871-6 [PMID: 9652685]
J Cosmet Dermatol. 2012 Dec;11(4):251-60 [PMID: 23174047]
Australas J Dermatol. 1995 Feb;36(1):13-5 [PMID: 7763215]
Lancet. 2012 Jan 28;379(9813):361-72 [PMID: 21880356]
Cutis. 2008 Mar;81(3):278-84 [PMID: 18441854]
J Am Acad Dermatol. 2016 May;74(5):945-73.e33 [PMID: 26897386]
Lancet. 2004 Dec 18-31;364(9452):2188-95 [PMID: 15610805]
Acta Derm Venereol. 1991;71(2):175-8 [PMID: 1675534]
Br J Dermatol. 1982 Jan;106(1):91-4 [PMID: 6460521]
Int J Dermatol. 1978 Apr;17(3):246-51 [PMID: 148436]
Dermatologica. 1988;177(2):109-14 [PMID: 2971582]
J Clin Aesthet Dermatol. 2009 Jul;2(7):26-9 [PMID: 20729967]
Med Clin (Barc). 1984 Nov 24;83(17):705-7 [PMID: 6240577]
J Dermatol. 2005 Mar;32(3):169-73 [PMID: 15863861]
Int J Clin Pharmacol Ther. 2012 Jun;50(6):434-7 [PMID: 22677304]
J Drugs Dermatol. 2010 Aug;9(8):998-1003 [PMID: 20684151]
Am J Clin Dermatol. 2016 Jun;17(3):293-303 [PMID: 26945741]
Curr Med Res Opin. 1989;11(7):453-62 [PMID: 2528439]
J Drugs Dermatol. 2013 Jun 1;12(6):644-9 [PMID: 23839180]
J Drugs Dermatol. 2009 Jul;8(7):624-30 [PMID: 19588638]
J Drugs Dermatol. 2007 Jun;6(6):616-22 [PMID: 17668527]
J Drugs Dermatol. 2012 Feb;11(2):174-80 [PMID: 22270198]
Int J Dermatol. 2006 Dec;45(12):1438-9 [PMID: 17184250]
Cutis. 2009 Aug;84(2):110-6 [PMID: 19746769]
J Dermatol. 2015 Oct;42(10):945-53 [PMID: 26211507]
Cutis. 2013 Feb;91(2):99-104 [PMID: 23513559]
Br J Dermatol. 1986 Sep;115(3):386 [PMID: 2944538]
J Am Acad Dermatol. 1997 Oct;37(4):590-5 [PMID: 9344199]
J Drugs Dermatol. 2013 Sep;12(9):1033-8 [PMID: 24002152]
J Drugs Dermatol. 2014 Sep;13(9):1083-9 [PMID: 25226009]
J Drugs Dermatol. 2012 Jun;11(6):714-22 [PMID: 22648218]
Soc Sci Med. 1985;20(4):425-9 [PMID: 3158080]
J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1261-8 [PMID: 27514932]
J Dermatolog Treat. 2002 Sep;13(3):111-7 [PMID: 12227873]
Dermatol Ther (Heidelb). 2014 Jun;4(1):61-70 [PMID: 24919432]
J Drugs Dermatol. 2012 Jul;11(7):818-24 [PMID: 22777222]
J Drugs Dermatol. 2009 Jul;8(7):657-61 [PMID: 19588642]
Dermatologica. 1982 Mar;164(3):201-8 [PMID: 6211379]
J Am Acad Dermatol. 2007 Nov;57(5):791-9 [PMID: 17655969]
Br J Dermatol. 2011 Aug;165(2):383-90 [PMID: 21495995]
Skinmed. 2006 Sep-Oct;5(5):219-23 [PMID: 16957432]
J Am Acad Dermatol. 2006 Sep;55(3):490-500 [PMID: 16908356]

MeSH Term

Acne Vulgaris
Adolescent
Adult
Benzoyl Peroxide
Cicatrix
Dermatologic Agents
Female
Humans
Male
Randomized Controlled Trials as Topic
Young Adult

Chemicals

Dermatologic Agents
Benzoyl Peroxide
Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Word Cloud

Similar Articles

Cited By